Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

The authors recommended having awareness of potential psychiatric AEs with the use of biologics in treating psoriasis or psoriatic arthritis, guiding toward more personalized and comprehensive ...

In the United States, people with skin of color wait longer for a psoriasis diagnosis, are more likely to have severe symptoms, and are less likely to use biologic therapy than white Americans.